Federal regulators approved a revolutionary pancreatic cancer treatment Wednesday that extends patient survival by more than double compared to chemotherapy alone, marking the first major breakthrough against one of America’s deadliest cancers in decades.
Treatment Doubles Patient Survival
The Food and Drug Administration granted approval to Revolution Medicines’ Rasonque for patients with advanced pancreatic cancer who have attempted at least one prior treatment. Clinical trials involving 500 patients demonstrated those receiving Rasonque alongside standard chemotherapy survived an average of 13.2 months, compared to roughly six months for chemotherapy-only patients. The drug targets a genetic mutation present in nearly all pancreatic cancer cases, finally cracking a problem that has stumped researchers for years.
Dr. Rachna Shroff, chief of hematology and oncology at the University of Arizona Cancer Center, reported she cried tears of joy upon reviewing the preliminary trial results in April. The oncologist called the breakthrough unprecedented for pancreatic cancer treatment, describing it as a complete game changer for physicians treating this aggressive disease.
Significant Side Effects Reported
Patients taking Rasonque experience substantial adverse reactions including severe blistering rashes, mouth and throat sores, vomiting, and diarrhea. Former Nebraska Senator Ben Sasse, who received the drug during clinical trials, described the skin reaction as nuclear-level in severity during a podcast interview. Despite these challenges, more than 2,000 patients have already accessed Rasonque through an expanded access program launched by Revolution Medicines in May, demonstrating desperate demand for effective treatment options.
Attacking Cancer’s Genetic Root
Rasonque works by targeting mutations in the KRAS gene, which functions as a cellular growth switch. In pancreatic and many other cancers, this mutation locks the switch in the on position, causing uncontrolled cell growth. The daily pill represents the first successful attempt to force this genetic switch back to its off position after years of failed research efforts. Pharmacologist Channing Der at the University of North Carolina called the approval a monumental moment, predicting additional advances will follow.
Facing America’s Third Deadliest Cancer
More than 67,000 Americans will receive pancreatic cancer diagnoses this year, according to the American Cancer Society. The disease ranks as the third leading cause of cancer death nationwide and carries the worst prognosis of all major cancers. With no screening tests available and vague early symptoms, most patients receive diagnoses only after the cancer has advanced significantly. The five-year survival rate for pancreatic adenocarcinoma stands at just eight percent. Revolution Medicines set the list price at $39,800 monthly before insurance coverage and discounts.
